Regen BioPharma Inc. Chairman Discusses the Rationale for Pursuing Autoimmune Indications by Activating the Nuclear Receptor NR2F6

18 months ago, Regen BioPharma Inc. (OTCQB: RGBP)(OTCQB: RGBPP) commenced a program to identify small molecules that inhibit the NR2F6 nuclear receptor. The NR2F6 nuclear receptor has been identified as a potentially very important immune cell inhibitor (an immune checkpoint) and cancer stem cell differentiator. Regen BioPharma believes that by inhibiting the NR2F6 nuclear receptor, […]